STOCK TITAN

Butterfly Network Reports Second Quarter 2025 Financial Results

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Delivered Highest Quarterly Revenue and Gross Margins in Company History 

  • Quarterly Revenue of $23.4 million in Q2, representing 9% YoY growth, and Gross Margins of 64%
  • Reduced quarterly Cash Used to $7.1 million, the lowest of any quarter
  • Revised full year Revenue guidance and improved Adjusted EBITDA guidance

BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)-- Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly” or the “Company”), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, today announced financial results for the second quarter ended June 30, 2025, and provided a business update.

Joseph DeVivo, Butterfly's President, Chief Executive Officer and Chairman commented, “Quarter 2 marked one year since we launched Butterfly iQ3, and I’m pleased to say we achieved a new high – our strongest revenue quarter in Company history at $23.4 million. We also reached record gross margins of 64% and had our lowest cash use yet at $7.1 million. It’s a real testament to the discipline of our team and the strength of our multi-pronged strategy – especially as we continue pushing toward breakeven in a challenging macro environment.”

DeVivo continued, “As we look ahead, we remain focused on scaling our core business, while unlocking new revenue streams by leveraging our existing technology. Handheld ultrasound is becoming a foundational part of care delivery, and with our Compass AI software coming soon, as well as our P5 chip and fourth-generation technology on the horizon, we're poised to continue leading that shift. We will continue innovating across hardware and software to expand adoption and maximize the value of the platform we’ve built.”

Recent Operational and Strategic Highlights:

  • Butterfly Garden Growth: Two new partners were added to the portfolio in Q2, while three existing partners received FDA clearance for their AI-powered clinical applications: iCardio, HeartFocus by DESKi, and Deep Echo. HeartFocus expects to launch to Butterfly users in Q3, with the other applications launching shortly thereafter.

  • New Educational Resources: Butterfly released a new Aorta Exam Protocol on its ScanLab™ educational software, helping users learn to scan for conditions like abdominal aortic aneurysms. Additionally, through Butterfly Garden, the University of Rochester Medical Center launched MSK VUE, an AI-powered musculoskeletal ultrasound training app for Butterfly devices, designed to help clinicians identify key peripheral structures.

  • Clinical Research: New research from Tufts University published in European Heart Journal - Imaging Methods and Practice demonstrated that a machine learning model specifically trained to work on Butterfly iQ+ devices can accurately detect aortic stenosis. Additionally, the full findings from the Rutgers Robert Wood Johnson Medical School and Robert Wood Johnson University Hospital study previewed earlier this year have now been accepted into a prominent medical journal for publication in Q3.

  • Announcing Compass AI: Next-generation, cloud-based enterprise software platform is expected to launch in Q3, and aims to further optimize documentation processes through new, advanced AI tools and other enhancements like automated voice control to capture caregivers' notes and auto-populate fields in seconds.

  • Butterfly HomeCare Progress: Concluded pilot program, which demonstrated meaningful reductions in readmissions for congestive heart failure patients being managed at risk. The Company and partner are now working toward completion of their first commercial agreement, aiming to deploy the Butterfly HomeCare solution in the partner's first state before the end of the year.

Three Months Ended June 30, 2025 Financial Results

Revenue: Total revenue was $23.4 million, up 9% from $21.5 million in the second quarter of 2024. U.S. revenue was $17.2 million, essentially flat to prior year, driven by the delivery of semiconductor chips to one of our Octiv partners and higher average selling prices, but partially offset by lower probe sales volume. International revenue increased 19% year-over-year to $6.2 million, driven by both price and volume due to the international launch of iQ3 during the third quarter of 2024.

Gross profit: Gross profit was $14.9 million versus $12.6 million in the prior year period. Gross margin increased to 63.7% from 58.6% in the prior year period. This increase was primarily due to the higher average selling prices and higher software and other services margins due to a reduction in software amortization and lower hosting costs.

Operating expenses: Operating expenses were $31.0 million, up 4% from $29.8 million in the prior year period. Total operating expenses excluding stock-based compensation and other expenses were $23.1 million, compared to $23.4 million in the prior year period, essentially flat to prior year.

Net loss: Net loss was $13.8 million, compared to $15.7 million in the prior year period.

Adjusted EBITDA: Adjusted EBITDA loss was $6.2 million, compared to $8.1 million in the prior year period.

Adjusted EPS: Adjusted EPS was $(0.03), compared to $(0.05) in the prior year period.

Cash and cash equivalents: Cash and cash equivalents were $148.1 million as of June 30, 2025.

Guidance

Revised Revenue guidance and improved Adjusted EBITDA guidance for the Fiscal Year 2025:

  • Revenue of $92 million to $96 million or approximately 15% growth
  • Adjusted EBITDA loss of $32 million - $37 million

Chief Financial and Operations Officer Transition

Effective today, August 1, 2025, Heather Getz, Chief Financial and Operations Officer, has resigned to pursue other interests. Ms. Getz will assist the Company to ensure a successful transition of her responsibilities prior to her departure. Her resignation is not the result of any disagreement regarding the Company’s operations, accounting, or other policies or practices.

Effective upon Ms. Getz’s resignation, Megan Carlson, Chief Accounting Officer and Senior Vice President of Finance and Accounting, will assume the roles of principal financial and accounting officer on an interim basis. Ms. Carlson has held various accounting and finance leadership positions at public companies in the SaaS and medical device industries and began her career in public accounting. She joined Butterfly in 2021 and has been instrumental in the Company’s financial and accounting functions, including most recently the equity offering completed in January and, earlier in her tenure, establishing the Company’s internal controls over financial reporting.

Butterfly has begun the process of engaging a search firm to assist in identifying Ms. Getz’s replacement.

“On behalf of our employees and Board of Directors, I want to thank Heather for her more than three years of dedicated service. We value the discipline she instilled across the organization, and under her leadership Butterfly strengthened its balance sheet and delivered on its financial commitments to shareholders. We wish her every success in her future endeavors,” said Butterfly CEO Joseph DeVivo. “I have the utmost confidence in Megan’s ability to lead our finance organization and ensure a seamless transition. Megan’s experience and deep understanding of our financial operations will be instrumental as we enter a new chapter for the company.”

“It has been a privilege to serve on Butterfly’s leadership team, and I am proud of our accomplishments during my tenure,” said Ms. Getz. “The dedicated team at Butterfly is well-positioned to continue executing on its strategic vision to create shareholder value.”

Reconciliation of GAAP to Adjusted

Reconciliations of gross margin to adjusted gross margin and of net loss to adjusted EBITDA and adjusted EPS for the three and six months ended June 30, 2025, and 2024 are provided in the financial schedules that are part of this press release. An explanation of these non-GAAP financial measures is also included below under the heading “Non-GAAP Financial Measures.”

Conference Call

A conference call and webcast to discuss second quarter 2025 financial performance and operational progress is scheduled for 8:00 am ET on August 1, 2025. The conference call will be broadcast live in listen-only mode via a webcast on Butterfly’s Investor Relations website at Events & Presentations. Individuals interested in listening to the conference call on your telephone may do so by dialing approximately ten minutes prior to start time:

US domestic callers: +1 833-470-1428
International (Toll): +1 404-975-4839
Global Dial-In Numbers: https://www.netroadshow.com/conferencing/global-numbers?confId=82507
Access Code: 685760

After the live webcast, the call will be archived on Butterfly’s Investor Relations page. In addition, a telephone replay of the call will be available until August 15, 2025, by dialing:

United States (Local): +1 929 458 6194
United States (Toll-Free): +1 866 813 9403
Access Code: 128350

About Butterfly Network

Butterfly Network, Inc. (NYSE: BFLY) is a healthcare company driving a digital revolution in medical imaging with its proprietary Ultrasound-on-Chip™ semiconductor technology and ultrasound software solutions. In 2018, Butterfly launched the world’s first handheld, single-probe, whole-body ultrasound system, Butterfly iQ. The iQ+ followed in 2020, and the iQ3 in 2024, each with improved processing power and performance by leveraging Moore’s Law. The iQ3 earned Best Medical Technology at the 2024 Prix Galien USA Awards, a prestigious honor and one of the highest accolades in healthcare. Butterfly’s innovations have also been recognized by Fierce 50, TIME’s Best Inventions and Fast Company’s World Changing Ideas, among other achievements.

Butterfly combines advanced hardware, intelligent software, AI, services, and education to drive adoption of affordable, accessible imaging. Clinical publications demonstrate that its handheld ultrasound probes paired with Compass™ enterprise workflow software, can help hospital systems improve care workflows, reduce costs, and enhance provider economics. With a cloud-based solution that enables care anywhere through next-generation mobility, Butterfly aims to democratize healthcare by addressing critical global healthcare challenges. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, the Middle East, North America and South America; to learn more about available countries, visit: https://www.butterflynetwork.com/choose-your-country.

Non-GAAP Financial Measures

In addition to providing financial measures based on generally accepted accounting principles in the United States of America (“GAAP”), we provide additional financial measures that are not prepared in accordance with GAAP (“non-GAAP”). The non-GAAP financial measures included in this press release are adjusted gross profit, adjusted gross margin, adjusted EBITDA, and adjusted EPS. We present non-GAAP financial measures in order to assist readers of our financial statements in understanding the core operating results that our management uses to evaluate the business and for financial planning purposes. Our non-GAAP financial measures provide an additional tool for investors to use in comparing our financial performance over multiple periods.

The non-GAAP financial measures included in this press release are key performance measures that our management uses to assess our operating performance. These non-GAAP measures facilitate internal comparisons of our operating performance on a more consistent basis. We use these performance measures for business planning purposes and forecasting. We believe that these non-GAAP measures enhance an investor’s understanding of our financial performance as they are useful in assessing our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business.

The non-GAAP financial measures included in this press release may not be comparable to similarly titled measures of other companies because they may not calculate these measures in the same manner. These non-GAAP financial measures are not prepared in accordance with GAAP and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. When evaluating the Company’s performance, you should consider adjusted gross profit, adjusted gross margin, adjusted EBITDA, and adjusted EPS alongside other financial performance measures prepared in accordance with GAAP, including gross profit, gross margin, net loss, and EPS.

The non-GAAP financial measures do not replace the presentation of our GAAP financial results and should only be used as a supplement to, not as a substitute for, our financial results presented in accordance with GAAP. In this press release, we have provided reconciliations of adjusted gross profit to gross profit, adjusted gross margin to gross margin, and adjusted EBITDA and adjusted EPS to net loss, the most directly comparable GAAP financial measures. Reconciliations of our non-GAAP financial measures to corresponding GAAP measures are not available on a forward-looking basis because we are unable to predict with reasonable certainty the non-cash component of employee compensation expense, changes in our working capital needs, variances in our supply chain, the impact of earnings or charges resulting from matters we consider not to be reflective, on a recurring basis, of our ongoing operations, and other such items without unreasonable effort. These items are uncertain, depend on various factors, and could be material to our results computed in accordance with GAAP. Management strongly encourages investors to review our financial statements and publicly filed reports in their entirety and not to rely on any single financial measure.

Forward Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Our actual results may differ from our expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believe,” “predict,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, our expectations with respect to financial results, future performance, commercialization and plans to deploy our products and services, including expectations regarding the launches of our Compass AI software, our P5 chip and fourth-generation technology, and the HeartFocus launch to Butterfly users, development of products and services, and the size and potential growth of current or future markets for our products and services. Forward-looking statements are based on our current beliefs and assumptions and on information currently available to us. These forward-looking statements involve significant known and unknown risks and uncertainties and other factors that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside our control and are difficult to predict. Factors that may cause such differences include, but are not limited to: our ability to grow and manage growth effectively; the success, cost, and timing of our product and service development activities; the potential attributes and benefits of our products and services; the degree to which our products and services are accepted by healthcare practitioners and patients for their approved uses; our ability to obtain and maintain regulatory approval for our products, and any related restrictions and limitations on the use of any authorized product; our ability to identify, in-license, or acquire additional technology; our ability to maintain our existing license, manufacturing, supply, and distribution agreements; our ability to compete with other companies currently marketing or engaged in the development of ultrasound imaging devices, many of which have greater financial and marketing resources than us; changes in applicable laws or regulations; the size and growth potential of the markets for our products and services, and our ability to serve those markets, either alone or in partnership with others; the pricing of our products and services, and reimbursement for medical procedures conducted using our products and services; our estimates regarding expenses, revenue, capital requirements, and needs for additional financing; our financial performance; our ability to attract and retain customers; our ability to manage our growth effectively; our ability to protect or enforce our intellectual property rights; our ability to maintain the listing of our Class A common stock on the New York Stock Exchange; and other risks and uncertainties indicated from time to time in our most recent Annual Report on Form 10-K or in subsequent filings that we make with the Securities and Exchange Commission. We caution that the foregoing list of factors is not exclusive. We caution you not to place undue reliance upon any forward-looking statements, which speak only as of the date of this press release. We do not undertake or accept any obligation or undertake to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based.

BUTTERFLY NETWORK, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except share and per share amounts)

(Unaudited)

 
Three months ended June 30, Six months ended June 30,

2025

2024

2025

2024

Revenue:
Product $

16,621

 

$

14,648

 

$

30,785

 

$

25,939

 

Software and other services

6,762

 

6,839

 

13,823

 

13,204

 

Total revenue

23,383

 

21,487

 

44,608

 

39,143

 

Cost of revenue:
Product

6,670

 

6,579

 

12,494

 

11,674

 

Software and other services

1,822

 

2,322

 

3,842

 

4,606

 

Total cost of revenue

8,492

 

8,901

 

16,336

 

16,280

 

Gross profit

14,891

 

12,586

 

28,272

 

22,863

 

Operating expenses:
Research and development

8,315

 

9,411

 

18,239

 

20,131

 

Sales and marketing

11,559

 

9,728

 

23,179

 

20,106

 

General and administrative

9,130

 

10,073

 

18,729

 

20,514

 

Other

1,987

 

606

 

2,691

 

1,964

 

Total operating expenses

30,991

 

29,818

 

62,838

 

62,715

 

Loss from operations

(16,100

)

(17,232

)

(34,566

)

(39,852

)

Interest income

1,503

 

1,291

 

3,155

 

2,802

 

Interest expense

(368

)

(309

)

(715

)

(609

)

Change in fair value of warrant liabilities

620

 

620

 

1,446

 

413

 

Other income (expense), net

531

 

(59

)

2,906

 

(201

)

Loss before provision for income taxes

(13,814

)

(15,689

)

(27,774

)

(37,447

)

Provision for income taxes

20

 

17

 

27

 

20

 

Net loss and comprehensive loss $

(13,834

)

$

(15,706

)

$

(27,801

)

$

(37,467

)

Net loss per common share attributable to Class A and B common stockholders, basic and diluted $

(0.06

)

$

(0.07

)

$

(0.12

)

$

(0.18

)

Weighted-average shares used to compute net loss per share attributable to Class A and B common stockholders, basic and diluted

248,393,811

 

211,663,554

 

241,695,884

 

210,268,501

 

BUTTERFLY NETWORK, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share amounts)

(Unaudited)

 

June 30,

2025

December 31,

2024

Assets
Current assets:
Cash and cash equivalents $

148,136

 

$

88,775

 

Accounts receivable, net of allowance for doubtful accounts of $2,726 and $2,583 at June 30, 2025 and December 31, 2024, respectively

24,527

 

20,793

 

Inventories

68,907

 

70,789

 

Current portion of vendor advances

4,555

 

5,547

 

Prepaid expenses and other current assets

7,622

 

6,709

 

Total current assets

253,747

 

192,613

 

Property and equipment, net

17,329

 

19,518

 

Intangible assets, net

8,216

 

8,916

 

Non-current portion of vendor advances

14,790

 

15,042

 

Operating lease assets

13,461

 

14,233

 

Other non-current assets

5,735

 

5,760

 

Total assets $

313,278

 

$

256,082

 

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable $

3,320

 

$

4,250

 

Deferred revenue, current

15,642

 

16,139

 

Accrued purchase commitments, current

131

 

131

 

Warrant liabilities, current

1,239

 

 

Accrued expenses and other current liabilities

24,334

 

27,695

 

Total current liabilities

44,666

 

48,215

 

Deferred revenue, non-current

7,231

 

7,315

 

Warrant liabilities, non-current

 

2,685

 

Operating lease liabilities

19,097

 

20,398

 

Other non-current liabilities

9,478

 

8,637

 

Total liabilities

80,472

 

87,250

 

Commitments and contingencies
Stockholders’ equity:
Class A common stock $.0001 par value; 600,000,000 shares authorized at June 30, 2025 and December 31, 2024; 224,609,833 and 188,626,154 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively

22

 

19

 

Class B common stock $.0001 par value; 27,000,000 shares authorized at June 30, 2025 and December 31, 2024; 26,426,937 shares issued and outstanding at June 30, 2025 and December 31, 2024

3

 

3

 

Additional paid-in capital

1,062,712

 

970,940

 

Accumulated deficit

(829,931

)

(802,130

)

Total stockholders’ equity

232,806

 

168,832

 

Total liabilities and stockholders’ equity $

313,278

 

$

256,082

 

BUTTERFLY NETWORK, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

 
Six months ended June 30,

2025

2024

Cash flows from operating activities:
Net loss $

(27,801

)

$

(37,467

)

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation, amortization, and impairments

4,442

 

5,217

 

Non-cash interest expense

713

 

607

 

Write-down of inventories

66

 

(81

)

Stock-based compensation expense

12,148

 

11,383

 

Change in fair value of warrant liabilities

(1,446

)

(413

)

Other

172

 

462

 

Changes in operating assets and liabilities:
Accounts receivable

(3,909

)

(3,165

)

Inventories

1,816

 

(1,072

)

Prepaid expenses and other assets

(874

)

165

 

Vendor advances

1,244

 

(1,396

)

Accounts payable

(927

)

(587

)

Deferred revenue

(581

)

(908

)

Change in operating lease assets and liabilities

(411

)

(348

)

Accrued expenses and other liabilities

(3,496

)

(3,064

)

Net cash used in operating activities

(18,844

)

(30,667

)

 
Cash flows from investing activities:
Purchases of property, equipment, and intangible assets, including capitalized software

(1,249

)

(1,872

)

Sales of property and equipment

 

35

 

Net cash used in investing activities

(1,249

)

(1,837

)

 
Cash flows from financing activities:
Proceeds from exercise of stock options and warrants

274

 

 

Proceeds from employee stock purchase plan

949

 

 

Net proceeds from share offering

81,006

 

 

Payments to tax authorities for restricted stock units withheld

(2,775

)

 

Net cash provided by financing activities

79,454

 

 

Net increase (decrease) in cash, cash equivalents, and restricted cash

59,361

 

(32,504

)

Cash, cash equivalents, and restricted cash, beginning of period

92,790

 

138,650

 

Cash, cash equivalents, and restricted cash, end of period $

152,151

 

$

106,146

 

BUTTERFLY NETWORK, INC.

ADJUSTED GROSS PROFIT AND ADJUSTED GROSS MARGIN

(In thousands)

(Unaudited)

 
Three months ended June 30, Six months ended June 30,

2025

2024

2025

2024

Revenue $

23,383

$

21,487

$

44,608

$

39,143

Cost of revenue

8,492

8,901

16,336

16,280

Gross profit $

14,891

$

12,586

$

28,272

$

22,863

 
Gross margin

63.7

%

58.6

%

63.4

%

58.4

%

 
Add:
Write-downs and write-offs of inventories

14

66

Adjusted gross profit $

14,905

$

12,586

$

28,338

$

22,863

 
Adjusted gross margin

63.7

%

58.6

%

63.5

%

58.4

%

 
Depreciation and amortization $

1,138

$

1,646

$

2,541

$

3,231

% of revenue

4.9

%

7.7

%

5.7

%

8.3

%

BUTTERFLY NETWORK, INC.

ADJUSTED EBITDA AND ADJUSTED EPS

(In thousands, except share and per share amounts)

(Unaudited)

 
Included on the condensed consolidated statements of operations and comprehensive loss as: Three months ended June 30, Six months ended June 30,

2025

2024

2025

2024

Net loss Net loss $

(13,834

)

$

(15,706

)

$

(27,801

)

$

(37,467

)

Stock-based compensation R&D, S&M, and G&A

5,864

 

5,859

 

12,148

 

11,383

 

Write-downs and write-offs of inventories Cost of revenue

14

 

 

66

 

 

Change in fair value of warrant liabilities Change in fair value of warrant liabilities

(620

)

(620

)

(1,446

)

(413

)

Other Other

1,987

 

606

 

2,691

 

1,964

 

Other expense (income), net Other income (expense), net

(531

)

59

 

(2,906

)

201

 

Adjusted net loss

(7,120

)

(9,802

)

(17,248

)

(24,332

)

Interest income Interest income

(1,503

)

(1,291

)

(3,155

)

(2,802

)

Interest expense Interest expense

368

 

309

 

715

 

609

 

Provision for income taxes Provision for income taxes

20

 

17

 

27

 

20

 

Depreciation and amortization Cost of revenue, R&D, S&M, and G&A

2,082

 

2,633

 

4,442

 

5,217

 

Adjusted EBITDA $

(6,153

)

$

(8,134

)

$

(15,219

)

$

(21,288

)

 
Adjusted EPS $

(0.03

)

$

(0.05

)

$

(0.07

)

$

(0.12

)

Weighted average shares used to compute adjusted EPS

248,393,811

 

211,663,554

 

241,695,884

 

210,268,501

 

 

Investors

Liz Learned Snyder

Director, Communications & Public Relations, Butterfly

investors@butterflynetwork.com

Steve Halper

Managing Director, LifeSci Advisors

shalper@lifesciadvisors.com

Source: Butterfly Network, Inc.

Butterfly Network Inc

NYSE:BFLY

BFLY Rankings

BFLY Latest News

BFLY Latest SEC Filings

BFLY Stock Data

447.59M
190.19M
14.88%
29.79%
5.07%
Medical Devices
X-ray Apparatus & Tubes & Related Irradiation Apparatus
Link
United States
BURLINGTON